Open Access Research article

Mutational profiling reveals PIK3CA mutations in gallbladder carcinoma

Vikram Deshpande1, Afamefuna Nduaguba3, Stephanie M Zimmerman1, Sarah M Kehoe2, Laura E MacConaill2, Gregory Y Lauwers1, Cristina Ferrone1, Nabeel Bardeesy1, Andrew X Zhu1* and Aram F Hezel3*

Author Affiliations

1 Massachusetts General Hospital, Harvard Medical School, 55 Fruit Street, Boston, Massachusetts 02114, USA

2 Center for Cancer Genome Discovery, Harvard Medical School, Dana-Farber Cancer Institute, 44 Binney Street, Boston, Massachusetts 02115, USA

3 James P. Wilmot Cancer Center, University of Rochester School of Medicine, 300 Elmwood Avenue, Rochester, NY 14642, USA

For all author emails, please log on.

BMC Cancer 2011, 11:60  doi:10.1186/1471-2407-11-60

Published: 8 February 2011

Additional files

Additional file 1:

Supplementary Table 1-3. Table S1: All mutations included in initial OncoMap screen. Table S2: Listing of mutations identified in initial OncoMap screening. 115 candidate mutations across 24 genes in 65% (47/72) of samples were identified. These were then ranked into two groups based on the mass spectrometric profiles and the likelihood that these represent true mutations referred to as conservative and aggressive "calls" which comprised 10% (12/115) and 90% (103/115) of possible mutations, respectively. Table S3: Candidate mutations across 12 genes (ABL1, APC, BRAF, EGFR, FGFR3, FLT3, KIT, KRAS, NRAS, PDGFRA, PIK3CA, MYC,) screened in hME validation assay on non WGA DNA using independent primers and probes.

Format: XLS Size: 61KB Download file

This file can be viewed with: Microsoft Excel Viewer

Open Data